Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis

Authors Baker S

Published 10 October 2008 Volume 2008:4(5) Pages 1079—1084


Review by Single-blind

Peer reviewer comments 3

Susan S Baker

Department of Pediatrics, University at Buffalo, Buffalo, NY, USA

Abstract: Pancreatic enzyme replacement therapy (PERT) is the only treatment for malabsorption in cystic fi brosis (CF) caused by pancreatic insufficiency (PI). PI occurs in approximately 85% of patients with CF. PERT overcomes some, but not all the signs and symptoms of malabsorption. Clinical parameters such as growth, abdominal pain, diarrhea and gassiness, commonly used to adjust PERT dosing, are shown not to be good indicators of their effectiveness. The FDA does not provide oversight of preparations of pancreatic enzymes consistent with the oversight it provides for all other drugs. The FDA intends to rectify this situation. Measures of the effectiveness of PERT are limited to the coefficient of fat absorption, a difficult and unpleasant exercise for patients.

Keywords: pancrelipase, cystic fibrosis, malabsorption, pancreatic enzymes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Pharmacological characterization of nanoparticle-induced platelet microaggregation using quartz crystal microbalance with dissipation: comparison with light aggregometry

Santos-Martinez MJ, Tomaszewski KA, Medina C, Bazou D, Gilmer JF, Radomski MW

International Journal of Nanomedicine 2015, 10:5107-5119

Published Date: 13 August 2015

Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects

Mizoue S, Nakano T, Fuse N, Iwase A, Matsumoto S, Yoshikawa K, IOP CHANGE Study Group

Clinical Ophthalmology 2014, 8:347-354

Published Date: 3 February 2014

Listeria monocytogenes endophthalmitis following keratoconjunctivitis

Shoughy SS, Tabbara KF

Clinical Ophthalmology 2014, 8:301-304

Published Date: 24 January 2014

Postural stability and quality of life after guided and self-training among older adults residing in an institutional setting

Tuunainen E, Rasku J, Jäntti P, Moisio-Vilenius P, Mäkinen E, Toppila E, Pyykkö I

Clinical Interventions in Aging 2013, 8:1237-1246

Published Date: 16 September 2013

The association of drooling and health-related quality of life in children with cerebral palsy

Chang SC, Lin CK, Tung LC, Chang NY

Neuropsychiatric Disease and Treatment 2012, 8:599-604

Published Date: 11 December 2012

Targeted dual-color silica nanoparticles provide univocal identification of micrometastases in preclinical models of colorectal cancer

Soster M, Juris R, Bonacchi S, Genovese D, Montalti M, Rampazzo E, Zaccheroni N, Garagnani P, Bussolino F, Prodi L, Marchiò S

International Journal of Nanomedicine 2012, 7:4797-4807

Published Date: 5 September 2012

Echographic detectability of optoacoustic signals from low-concentration PEG-coated gold nanorods

Conversano F, Soloperto G, Greco A, Ragusa A, Casciaro E, Chiriacò F, Demitri C, Gigli G, Maffezzoli A, Casciaro S

International Journal of Nanomedicine 2012, 7:4373-4389

Published Date: 9 August 2012

Diagnostic accuracy of dual-source CT angiography and coronary risk stratification

Xia Yang, Lu-yue Gai, Ping Li, et al

Vascular Health and Risk Management 2010, 6:935-941

Published Date: 14 October 2010

Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus

Toshihiro Tsuruda, Johji Kato, Takahiro Sumi, Kazuya Mishima, Hiroyuki Masuyama, Hiroyuki Nakao, Takuroh Imamura, Tanenao Eto, Kazuo Kitamura

Vascular Health and Risk Management 2007, 3:417-423

Published Date: 15 September 2007